Non-Viral / Intracellular Drug Delivery Systems Global Market Report 2022: Featuring 20Med Therapeutics, AstraZeneca, BioNTech, Deloitte & More

Rhea-AI Summary

The report titled "Non-Viral / Intracellular Drug Delivery Systems Market" by ResearchAndMarkets.com highlights the rising demand for efficient drug delivery systems in the biopharmaceutical industry. It notes that over 20% of the proteome resides within cell membranes, necessitating innovative delivery methods for therapeutic intervention. Key advancements include non-viral systems such as exosome-based techniques and cell-penetrating peptides. The report reveals that around 1,300 patents have been filed, indicating substantial innovation, with over 20,000 studies on oligonucleotide-based therapeutics underway. The market is expected to grow significantly in the near term.

Positive

• Emerging need for intracellular drug delivery systems in biopharmaceuticals.
• Over 20,000 ongoing studies on oligonucleotide-based therapeutics.
• 1,300 patents filed for non-viral drug delivery technologies, indicating innovation in the field.

Negative

• None.

DUBLIN, Jan. 19, 2023 /PRNewswire/ -- The "Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule, Type of Biologics Delivered, Type of Vehicle Used, Type of Therapeutic Area, Type of Payments and Key Geographies: Industry Trends and Global Forecasts, 2023-2035" report has been added to  ResearchAndMarkets.com's offering.

In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry. Targeting the delivery of a pharmacological substance to its intended physiological site of action ensures that adequate concentration of the therapeutics is made available, in order to elicit the desired clinical benefits and limit off-target / systemic toxicity. In fact, a study suggests that over 20% of the proteome, including oncogenic proteins, cell metabolism regulators, components of different signal transduction pathways and enzymes, is localized within the cell membrane.

Further, considering the fact that only 10% of the human genome can selectively bind to small molecule pharmaceuticals, industry experts believe that intracellular biologics, particularly nucleic acid-based therapeutic interventions, present a promising alternative to conventional therapies. Furthermore, recent advancements in cell biology and intracellular delivery systems have led to the identification of several potential therapeutic targets for a variety of clinical disorders.

These targets have been demonstrated to be capable of aiding the treatment of disease indications which were previously considered incurable, as they were localized within the confines of the cell membrane. It is also worth highlighting that majority of the available biopharmaceutical interventions, such as gene therapies, require cell membrane permeabilization in order to mediate their therapeutic effects.

Gene delivery systems are usually based on viral and non-viral vectors and known to enable the entry of pharmacologically active compounds into the matrix of the cytoplasm. Specifically, viral drug delivery systems utilize the ability of viruses to inject their DNA inside host cells. However, such systems are often fraught with several challenges, such as immunogenicity, toxicity and reverse mutation.

In order to overcome the aforementioned challenges and enable the delivery of intracellular biologics, researchers have developed various non-viral delivery systems, including exosome-based drug delivery techniques, cell-penetrating peptides (CPP) and nanoparticle-based processes. Further, numerous technology developers have signed several strategic agreements with therapy developers in order to facilitate the development of drug formulations that can be delivered to the intracellular matrix.

Additionally, close to 1,300 patents related to such technologies have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain.

At present, more than 20,000 oligonucleotide-based therapeutics focused studies are being conducted across the globe. In this context, it is also worth mentioning that, recently, Novartis received the USFDA approval for Leqvio (inclisiran), a first-in-class siRNA therapy for lower LDL cholesterol, which is delivered using an intracellular drug delivery technology. Other examples of recently approved gene therapies that are being delivered intracellularly include (alphabetical order) ABECMA (idecabtagene vicleucel; manufactured by Celgene), BREYANZI (lisocabtagene maraleucel; manufactured by Juno Therapeutics) and KYMRIAH (tisagenlecleucel; manufactured by Novartis).

Driven by a growing demand for systems that can efficiently deliver therapeutic interventions in intracellular spaces, the non-viral drug delivery systems market is likely to witness significant growth in the short to mid-term.

Frequently Asked Questions

• Who are the leading players engaged in the development of intracellular drug delivery technologies?
• Which partnership models are commonly adopted by stakeholders engaged in this domain?
• What type of molecule can be delivered using intracellular drug delivery technologies?
• How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
• How is the current and future market opportunity likely to be distributed across key market segments and geographical region?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. KEY INSIGHTS

6. COMPANY COMPETITIVENESS ANALYSIS

7. COMPANY PROFILES

8. PATENT ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. PUBLISHER FRAMEWORK: BCG, ANSOFF AND KALBACH INNOVATION MODEL

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

• 20Med Therapeutics
• Abcam
• Acuitas Therapeutics
• Acceleron Pharma
• Adocia
• AgonOx
• Alcobra (Acquired by Arcturus Therapeutics)
• Aldevron
• Alexion Pharmaceuticals
• Almirall
• Alnylam Pharmaceuticals
• AM Chemicals
• Amgen
• Anjarium Biosciences
• Aqdot
• Aquarius Biotechnologies
• Arcturus Therapeutics
• Arrowhead Pharmaceuticals
• Aruna Bio
• Ascendis Pharma
• Astellas Innovation Management (A subsidiary of Astellas Pharma)
• Astellas Pharma
• AstraZeneca
• Avectas
• Avellino Lab
• Avicenna Oncology
• Avidity Biosciences
• Baseceuticals (Division of Creative Biogene)
• Basilard BioTech
• Bavarian Nordic
• BeiGene
• Bicycle Therapeutics
• BioCellChallenge
• BioGene
• BioMarin Pharmaceuticals
• BioMoti
• Biond Biologics
• Bioneer
• BioNet-Asia
• BioNTech
• Biopact Ventures
• Bio-Path Holdings
• Bio-Techne
• BOC Sciences
• Carisma Therapeutics
• Carmine Therapeutics
• Catamaran Bio
• CCRM
• Celanese
• Cell and Gene Therapy Catapult
• Cellectar Biosciences
• Cellics Therapeutics
• Center for Cancer Immune Therapy (Herlev Hospital)
• Centre for Process Innovation
• CEPI
• Chimeron Bio
• Code Biotherapeutics
• Codiak BioSciences
• CQDM
• Cristal Therapeutics
• Croda
• Crucell (A subsidiary of Johnson & Johnson)
• CureVac
• Cybrexa Therapeutics
• CyGenica
• Cytiva
• DCprime (Acquired by Van Herk Investments)
• Deloitte
• Dicerna Pharmaceuticals
• Duke-NUS Medical School
• Editas Medicine
• Effimune
• Eisai
• Elasmogen
• Eli Lilly
• And More

For more information about this report visit https://www.researchandmarkets.com/r/ucht35

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/non-viral--intracellular-drug-delivery-systems-global-market-report-2022-featuring-20med-therapeutics-astrazeneca-biontech-deloitte--more-301726191.html

SOURCE Research and Markets

FAQ

What is the future outlook for the non-viral drug delivery systems market?

The market is expected to witness significant growth in the short to mid-term due to rising demand for efficient therapeutic interventions.

What challenges are associated with viral drug delivery systems?

Viral systems face challenges like immunogenicity, toxicity, and reverse mutation, prompting the development of non-viral alternatives.

What advancements have been made in intracellular drug delivery technologies?

Recent advancements include non-viral delivery systems such as cell-penetrating peptides and exosome-based techniques.

How many therapeutic studies are focused on oligonucleotide-based therapeutics?

Currently, there are over 20,000 studies being conducted on oligonucleotide-based therapeutics globally.

Which companies are leading in intracellular drug delivery technologies?

Key players include AstraZeneca, BioNTech, and 20Med Therapeutics among others developing innovative drug delivery technologies.